Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage

Key Points Question What is the association between prior oral anticoagulant use (factor Xa [FXa] inhibitors, warfarin, or none) and in-hospital outcomes among patients with nontraumatic intracerebral hemorrhage (ICH)? Findings In this registry-based cohort study of 219 701 patients with ICH, prior use of FXa inhibitors was associated with higher in-hospital mortality vs no prior anticoagulant use, although FXa inhibitors were associated with lower in-hospital mortality than warfarin. Meaning These findings suggest that patients with FXa inhibitor–associated ICH have a higher risk of mortality than those not taking an oral anticoagulant but better outcomes than those with warfarin-related ICH.

[1]  G. Brophy,et al.  Factor Xa Inhibitor-Related Intracranial Hemorrhage , 2020, Circulation.

[2]  Hugh Calkins,et al.  Correction to: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Circulation.

[3]  T. Steiner,et al.  European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage , 2019, European stroke journal.

[4]  B. Kim,et al.  Intracerebral hemorrhage associated with warfarin versus non-vitamin K antagonist oral anticoagulants in Asian patients , 2019, Journal of Clinical Neuroscience.

[5]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[6]  Eric E. Smith,et al.  Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality , 2018, JAMA.

[7]  G. Breithardt,et al.  Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). , 2017, The American journal of cardiology.

[8]  C. Held,et al.  Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. , 2017, Blood.

[9]  Michael J Pencina,et al.  Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation , 2017, JAMA.

[10]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[12]  J. Teitelbaum,et al.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage , 2016, Neurocritical Care.

[13]  D. Werring,et al.  Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type , 2016, Neurology.

[14]  H. Tomita,et al.  Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment: Comparison With Those During Warfarin , 2014, Stroke.

[15]  E. Antman,et al.  Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 , 2014, Stroke.

[16]  Manesh R. Patel,et al.  Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation , 2014, Stroke.

[17]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[18]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[19]  Eric E. Smith,et al.  Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. , 2012, American heart journal.

[20]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[21]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[22]  Eric E. Smith,et al.  Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010, Circulation. Cardiovascular quality and outcomes.

[23]  A. Rabinstein.  Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010 .